APDN Valuation

Applied DNA Sciences Inc

Add to Watchlist

Advanced Chart

4.180

-0.37(-8.132%)1D

Overview
Forecast
Valuation
Earnings

APDN Relative Valuation

APDN's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, APDN is overvalued; if below, it's undervalued.

Historical Valuation

Applied DNA Sciences Inc (APDN) is now in the Undervalued zone, suggesting that its current forward PS ratio of 0.37 is considered Undervalued compared with the five-year average of -2.86. The fair price of Applied DNA Sciences Inc (APDN) is between 15.63 to 43.62 according to relative valuation methord. Compared to the current price of 4.22 USD , Applied DNA Sciences Inc is Undervalued By 73%.

Relative Value

Fair Zone

15.63-43.62

Current Price：4.22

73%

Undervalued

-0.02

Trailing

Forward

0.00

EV/EBITDA

Applied DNA Sciences Inc. (APDN) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward EV/EBITDA of 0.00 falls within the Strongly Undervalued range.

0.39

EV/EBIT

Applied DNA Sciences Inc. (APDN) has a current EV/EBIT of 0.39. The 5-year average EV/EBIT is -1.56. The thresholds are as follows: Strongly Undervalued below -5.90, Undervalued between -5.90 and -3.73, Fairly Valued between 0.61 and -3.73, Overvalued between 0.61 and 2.78, and Strongly Overvalued above 2.78. The current Forward EV/EBIT of 0.39 falls within the Historic Trend Line -Fairly Valued range.

0.35

Applied DNA Sciences Inc. (APDN) has a current PS of 0.35. The 5-year average PS is 2.19. The thresholds are as follows: Strongly Undervalued below -0.91, Undervalued between -0.91 and 0.64, Fairly Valued between 3.73 and 0.64, Overvalued between 3.73 and 5.28, and Strongly Overvalued above 5.28. The current Forward PS of 0.35 falls within the Undervalued range.

0.00

P/OCF

Applied DNA Sciences Inc. (APDN) has a current P/OCF of 0.00. The 5-year average P/OCF is 2.44. The thresholds are as follows: Strongly Undervalued below -27.16, Undervalued between -27.16 and -12.36, Fairly Valued between 17.25 and -12.36, Overvalued between 17.25 and 32.05, and Strongly Overvalued above 32.05. The current Forward P/OCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.

0.00

P/FCF

Applied DNA Sciences Inc. (APDN) has a current P/FCF of 0.00. The 5-year average P/FCF is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward P/FCF of 0.00 falls within the Strongly Undervalued range.

Applied DNA Sciences Inc (APDN) has a current Price-to-Book (P/B) ratio of 0.17. Compared to its 3-year average P/B ratio of -3.85 , the current P/B ratio is approximately -104.43% higher. Relative to its 5-year average P/B ratio of -0.68, the current P/B ratio is about -125.13% higher. Applied DNA Sciences Inc (APDN) has a Forward Free Cash Flow (FCF) yield of approximately -587.03%. Compared to its 3-year average FCF yield of -172.06%, the current FCF yield is approximately 241.18% lower. Relative to its 5-year average FCF yield of -122.86% , the current FCF yield is about 377.80% lower.

0.18

P/B

Median3y

-3.85

Median5y

-0.68

-634.21

FCF Yield

Median3y

-172.06

Median5y

-122.86

Competitors Valuation Multiple

The average P/S ratio for APDN's competitors is 3.68, providing a benchmark for relative valuation. Applied DNA Sciences Inc Corp (APDN) exhibits a P/S ratio of 0.35, which is -90.56% above the industry average. Given its robust revenue growth of 5.78%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

APDN.O

Applied DNA Sciences Inc

Entero Therapeutics Inc

Loss

2.10M

AQB.O

AquaBounty Technologies Inc

Performance Decomposition

Market capitalization of APDN decreased by 99.71% over the past 1 year. The primary factor behind the change was an increase in Revenue Growth from 929.63K to 983.37K.

The secondary factor is the Margin Expansion, contributed -29.82%to the performance.

Overall, the performance of APDN in the past 1 year is driven by Revenue Growth. Which is more sustainable.

5.78%

929.63K → 983.37K

Revenue Growth

-29.82%

-483.39 → -339.25

Margin Expansion

-75.67%

-0.02 → 0.00

P/E Change

-99.71%